Project Grant R41CA217551

The National Institute on Aging (NIA) awarded a $949,062 Project Grant (CFDA 93.866) to Somatoceutics LLC to develop a non-toxic, peptide-based nanomaterial (SMC-101 nanotubes) for delivering drugs across the blood-brain barrier to treat Alzheimer's disease and other dementias. The objectives are to optimize the nanotubes for drug-loading and transcytosis across a blood-brain barrier model in vitro, and then evaluate their toxicity and ability to deliver the drug galantamine to the central...

The U.S. National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $349,908 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to Evanesc Therapeutics, Inc. to develop a non-invasive medical device designated "EvaPERMEA" that uses low-power radio frequency evanescent waves to temporarily permeabilize the blood-brain barrier. This innovation aims to improve the delivery of therapeutic...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded Cordance Medical Inc. a $999,125 Project Grant on September 11, 2025 to develop the "NeuroAccess" system, a focused ultrasound device designed for safe, temporary, and non-invasive blood-brain barrier (BBB) opening. This technology enables a novel liquid biopsy technique called "sonobiopsy" to improve the clinical management of malignant brain tumor patients by providing timely...

The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,998 to Neonc Technologies Inc. to support the development of NEO212, a novel oral drug for the treatment of acute myeloid leukemia (AML). The goal is to perform studies towards an Investigational New Drug (IND) submission to the FDA, in order to validate the drug's promising anti-cancer activity and favorable safety profile observed in preclinical AML models. Key products and...

This $1,296,385 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to accelerate the translation and commercialization of a novel, non-invasive wearable rotating magnetic field therapy device (ONCOMAGNETIC DEVICE or OMTX) targeting the treatment of brain cancers. The device generates spinning oscillating magnetic fields that have demonstrated strong, selective anti-cancer effects on patient-derived glioblastoma (GBM) cells and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $400,000 to Senex Biotechnology Inc. to develop a nanoparticle formulation of a mediator kinase inhibitor drug candidate, SNX631-6, for the treatment of peritoneal ovarian cancer metastases. The goal is to optimize the nanoparticle formulation for improved pharmacokinetics and efficacy compared to oral administration when delivered intraperitoneally. The project will assess the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $399,970 to Duo Oncology Inc. to develop DUO-207, an ultrasmall nanoparticle formulation designed to improve the delivery and efficacy of combination chemotherapy for advanced pancreatic cancer. The key product being developed under this award is DUO-207, which combines a polymer-conjugated gemcitabine and paclitaxel in a single 14nm nanoparticle. This novel formulation...

This Project Grant award of $163,640 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to develop novel non-viral gene delivery platforms for the treatment of glioblastoma, an aggressive brain cancer. The study aims to investigate the use of brain-penetrating nanoparticles modified to target tumor cells, and to further optimize gene delivery through focused ultrasound treatment. The research is being conducted at the University of Virginia,...

This $399,358 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cordance Medical Inc. aims to optimize a non-invasive focused ultrasound system, called the "NeuroAccess System," to enable liquid biopsies for brain tumor patients. The key objectives are to demonstrate the safety of repeatedly opening the blood-brain barrier, optimize the opening volume and technique in a rat glioma model, and confirm the system's ability to...